Use of Luteal Phase Support

In: Controversies in Assisted Reproduction · 2020 · pp. 71–85 · doi:10.1201/9781351241694-8 · W3007432668
book-chapter OA: closed CC0
View on OpenAlex View at publisher

Abstract

Luteal phase support is becoming a highly personalized treatment based on each stimulation protocol and patient characteristics. After the application of human chorionic gonadotrophin (hCG) for final oocyte maturation, the vaginal route for progesterone administration is sufficient to maintain an adequate luteal phase support. Luteolysis after gonadotropin releasing hormone (GnRH) agonist trigger is patient specific and not always severe. According to the progesterone level, individualized luteal phase support with low dosages of hCG can be applied without the risk of ovarian hyperstimulation syndrome (OHSS) development. It is the task of the reproductive medicine specialist to individualize luteal phase support according to the patient's specific characteristics, needs, and desires and the type of treatment performed.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK